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Abstract
Background: The bronchial asthma, a clinical complication of persistent inflammation of the airway and subsequent airway
hyper-responsiveness, is a leading cause of morbidity and mortality in critically ill patients. Several studies have shown that
oxidative stress plays a key role in initiation as well as amplification of inflammation in airways. However, still there are no
good anti-oxidant strategies available for therapeutic intervention in asthma pathogenesis. Most recent studies suggest that
polyol pathway enzyme, aldose reductase (AR), contributes to the pathogenesis of oxidative stress–induced inflammation
by affecting the NF-kB-dependent expression of cytokines and chemokines and therefore inhibitors of AR could be anti-
inflammatory. Since inhibitors of AR have already gone through phase-III clinical studies for diabetic complications and
found to be safe, our hypothesis is that AR inhibitors could be novel therapeutic drugs for the prevention and treatment of
asthma. Hence, we investigated the efficacy of AR inhibition in the prevention of allergic responses to a common natural
airborne allergen, ragweed pollen that leads to airway inflammation and hyper-responsiveness in a murine model of
asthma.
Methods and Findings: Primary Human Small Airway Epithelial Cells (SAEC) were used to investigate the in vitro effects of
AR inhibition on ragweed pollen extract (RWE)-induced cytotoxic and inflammatory signals. Our results indicate that
inhibition of AR prevents RWE -induced apoptotic cell death as measured by annexin-v staining, increase in the activation of
NF-kB and expression of inflammatory markers such as inducible nitric oxide synthase (iNOS), cycloxygenase (COX)-2,
Prostaglandin (PG) E2, IL-6 and IL-8. Further, BALB/c mice were sensitized with endotoxin-free RWE in the absence and
presence of AR inhibitor and followed by evaluation of perivascular and peribronchial inflammation, mucin production,
eosinophils infiltration and airway hyperresponsiveness. Our results indicate that inhibition of AR prevents airway
inflammation and production of inflammatory cytokines, accumulation of eosinophils in airways and sub-epithelial regions,
mucin production in the bronchoalveolar lavage fluid and airway hyperresponsiveness in mice.
Conclusions: These results suggest that airway inflammation due to allergic response to RWE, which subsequently activates
oxidative stress-induced expression of inflammatory cytokines via NF-kB-dependent mechanism, could be prevented by AR
inhibitors. Therefore, inhibition of AR could have clinical implications, especially for the treatment of airway inflammation, a
major cause of asthma pathogenesis.
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Introduction
There has been a significantly increased prevalence of asthma
over the last few decades, specifically in developing countries [1].
This appears to be related to changes in the environment that
affects susceptible individuals, both in the induction and worsening
of established disease [2]. Epidemiological studies identified
multiple interacting risk factors, including inhaled pollutants such
as environmental tobacco smoke, particulate matter, oxides of
nitrogen, ozone, and repeated respiratory virus exposures, which
induce and/or augment reactive oxygen species (ROS) generation
in the airways [3]. Although lung has excellent antioxidative
system, in the presence of excessive ROS the cells become
oxidatively stressed leading to loss of intracellular redox homeo-
stasis, additional ROS production, alterations in cellular signaling
and pathological processes [4,5]. In addition, during inflammatory
processes more ROS are generated by activated mast cells,
macrophages, eosinophils, and neutrophils that have the potential
to injure airway lining cells [6,7]. Cellular oxidative stress plays a
fundamental role in inflammation through the activation of stress
kinases such as MAPKs, which comprise a large family of protein
kinases including ERK1 (p44
MAPK)/ERK2 (p42
MAPK) and JNK,
which activate redox-sensitive transcription factors such as NF-kB
and AP-1 [8]. The transcription factors bind to DNA and
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6535transcribe inflammatory proteins such as cytokines, chemokines,
iNOS and COX-2.
Our recent studies have shown that ROS-induced NF-kB
activation is mediated by aldose reductase-catalyzed products of
lipid aldehyde-glutathione conjugates [9,10]. Aldose reductase
(AR; AKR1B1), a member of aldo-keto reductase superfamily,
besides reducing glucose to sorbitol, efficiently reduces lipid
aldehydes and their gluthathione conjugates [11]. Most impor-
tantly, we have shown that AR-catalyzed reduced product of
lipid aldehyde-glutathione conjugates such as glutathionyl-1,4-
dihydroxynonane (GS-DHN) mediates NF-kB activation indi-
cating that the inhibition of this enzyme could prevent
inflammatory responses [10]. Pharmacological inhibition or
siRNA ablation of AR attenuates TNF-a-a n dg r o w t hf a c t o r -
induced IkBa phosphorylation and degradation and resultant
activation of NF-kB thereby preventing the cytotoxic effects in
vascular smooth muscle cells (VSMC), vascular endothelial cells
(VEC) and human lens epithelial cells (HLEC) [12–15]. Further,
our studies have shown that hyperglycemia and endotoxin-
induced increase in inflammatoryc y t o k i n e sa n dc h e m o k i n e si n
both cellular and animal models (such as restenosis, colon cancer
and uveitis) is efficiently prevented by AR inhibitors [9,16,17].
These results suggest that AR inhibitors, initially developed as
anti-diabetic drugs, could be used as therapeutic intervention to
prevent inflammation [11]. AR inhibitors such as zopolrestat and
fidarestat have been found to be safe and passed in FDA’s Phase-I
clinical trials for diabetic neuropathy but failed in Phase-III
clinical trials as they have been shown to be not as effective,
though they did not have any major side effects [18]. Our recent
results demonstrate that AR inhibitors could have therapeutic
use for the prevention and treatment of inflammatory disorders
other than diabetic complications such as asthma, an airway
inflammatory disease [11]. For such use a careful examination of
the effect of AR inhibition in clinically relevant animal models is
mandatory. We have used short ragweed (Ambrosia artemisiifolia)
pollen extract, one of the most abundant aeroallergen that causes
severe seasonal allergic symptoms in the United States, Canada
and Europe, to elicit allergic responses via induction of oxidative
stress that mimics airway inflammation in humans [19–21]. In
the present study, we investigated whether treatment with AR
inhibitors could prevent alterations in the cytokine and
chemokine levels in a cellular model using human SAEC and a
clinically relevant mice model which mimics allergic airway
inflammatory conditions in humans. Our results indicate that AR
inhibitors are powerful repressors of the expression of major
cytokines and chemokines in a mouse model of ragweed–induced
allergic airway inflammation that leads to asthma.
Results
AR Inhibition prevents RWE-Induced apoptosis in SAEC
The airway epithelium plays an important function as a barrier to
foreign particles, pollens, spores of fungi and other xenobiotics which
disturb cellular redox homeostasis leading to apoptosis of airway
epithelial cells [22–24,29,33]. Hence, we first determined the effect of
AR inhibition on RWE–induced cell death of SAEC by Annexin-V
binding assay. Annexin-V binds to the inverted phosphotedylserine in
the cells undergoing apoptosis. Propidium-iodide (PI) was used as the
indicator of the cell mortality. In SAEC, RWE-treatment caused
increased cell death (over 50%) in 18 h as compared to the control
cells. Pre-incubation of the cells with AR inhibitor, zopolrestat,
significantly (p,0.01) prevented RWE-induced cell death by .80%
(Fig. 1B). Under similar conditions, AR inhibition alone did not cause
apoptosis of SAEC.
AR inhibition decreases RWE-induced ROS formation in
SAEC
It has been reported that addition of RWE to cultured epithelial
cells or airways increases oxidative stress levels within minutes after
exposure [21,25]. To examine the nature of the RWE-induced
decrease in SAEC viability, we measured the level of ROS in RWE-
induced SAEC and whether AR inhibitors could prevent it. As shown
in Fig. 2, RWE (150 mg/mL) caused increase in cellular ROS levels
as evident by increased fluorescence by ROS sensitive dihydroethi-
dium (DHE). Pre-incubation of SAEC with two different AR
inhibitors, sorbinil or zopolrestat, prevented these changes (Fig. 2).
Under the similar conditions, AR inhibition alone caused no
significant change in the ROS levels in SAEC. These results suggest
that inhibition of AR increased antioxidant potential of cells and
prevented RWE-induced increase in ROS and resultant cell death.
AR inhibition prevents RWE-induced production of
inflammatory cytokines and chemokines in SAEC
Since RWE is known to elevate the levels of inflammatory
markers in the airway epithelial cells that cause inflammation and
aggravate the allergic condition [25], we next examined the effect of
AR inhibition on the RWE-induced increase in the levels of selected
inflammatory markers in SAEC culture medium. As shown in
Fig. 3(I) A and B, treatment of SAEC with RWE (150 mg/mL) for
24 h caused 3 and 4-fold increase in the synthesis of IL-6, and IL-8,
respectively, and inhibition of AR by pharmacological agents
significantly prevented the increase. A more than 2-fold increase in
the RWE-induced PGE2 levels in SAEC was also significantly
(.75%) prevented by AR inhibition (Fig. 3(I) C).
Although zopolrestat is a specific inhibitor of AR, to rule out its
non-specific response in the biological system, we ablated AR
message in SAEC by antisense oligonucleotides (AR siRNA) and
studied whether phenotypic absence of AR will have similar effects
in SAEC as did AR inhibitor in protection against RWE-induced
inflammation. Transient transfection of SAEC with AR siRNA
abolished AR protein by .95% (Fig. 3(II) A–C, inset) while with
scrambled siRNA oligonucleotides AR expression did not change.
We observed that siRNA ablation of AR also significantly
prevented RWE-induced synthesis of cytokines such as IL-6, and
chemokines IL-8 and PGE2 in SAEC (Fig. 3(II) A–C). We further
examined the effects of AR inhibition on the expression of
inflammatory markers at RNA levels using quantitative RT-PCR.
As shown in Fig. 3(III) A&B, treatment of SAEC with RWE caused
a 3–4 fold increase in the expression of IL-6 and IL-8 mRNA level
and zopolrestat prevented it by .70% suggesting that AR could
regulate the transcriptional activation of inflammatory marker
genes. Also, since PGE2 is synthesized by inducible cycloxygenase
(COX)-2, we determined the effect of AR inhibition on the
transcriptional activation of COX-2 by quantification of its
mRNA in response to RWE in SAEC by RT-PCR. As shown in
Fig. 3(III) C, RWE significantly increased the mRNA levels of
COX-2 in SAEC and zopolrestat prevented it by more than 60%.
These results suggest that AR regulates the synthesis as well as
expression of inflammatory markers.
AR inhibition prevents RWE-induced expression of
inflammatory markers in SAEC
Since biosynthesis of PGE2 and NO from their precursors is
catalyzed by COX-2 and iNOS enzymes respectively, we next
examined the effect of AR inhibition on RWE-induced COX-2
and iNOS expression in SAEC by immunoblotting. As shown in
Fig. 4(I) A, treatment of SAEC with RWE significantly (,3-folds)
increased COX-2 and iNOS protein expression and pre-treatment
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PLoS ONE | www.plosone.org 2 August 2009 | Volume 4 | Issue 8 | e6535Figure 1. Inhibition of AR prevents RWE-induced apoptosis and cell death in SAEC. (A) Growth-arrested SAEC, pretreated without or with
zopolrestat (20 mM), were incubated with 150 mg/ml of RWE for 18 h to induce apoptotic cell death. The cells were stained with annexin-V FITC (FL-1)
and propidium iodide (PI) (FL-2). R1 denotes dead cells (PI positive), R2 represents early apoptotic cells (annexin-V positive) and R1+R2 represents
total dead cells. (B) The data from (A) has been plotted as bar diagram (n=4,
*p,0.01 Vs Control;
**p,0.01 Vs RWE). RWE, ragweed pollen extract; zop,
zopolrestat.
doi:10.1371/journal.pone.0006535.g001
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prevented the increase. This indicates that RWE-induced COX-2
and iNOS overexpression is mediated by AR, which is obligatory
for RWE-induced PGE2 and NO production that exacerbate
allergic inflammation.
AR inhibition prevents RWE-induced alterations in pro-
and anti-apoptotic proteins in SAEC
Since apoptosis is regulated by the fine balance between the pro-
apoptotic and anti-apoptotic proteins, we next examined the effect
of AR inhibition on the expression of these proteins. As shown in
Figure 2. Inhibition of AR prevents RWE-induced ROS generation in SAEC. Approximately 1610
5 cells were seeded on 2-chambered slides
and starved in serum-free basal medium with or without AR inhibitors, sorbinil or zopolrestat, for 24 h. The cells were treated with RWE (150 mg/ml)
for 16 h. The SAEC were washed with cold PBS (pH 7.2) and stained with ROS-sensitive dye, dihydroethidium (DHE) for 15 min at 37uC. The cells were
washed again and mounted with floursave (with diamidino-2-phenylindole (DAPI)) mounting medium. Photomicrographs were acquired by a
fluorescence microscope (Nikon). A representative picture is given (n=4); Magnification 2006. ARI, aldose reducatse inhibitor.
doi:10.1371/journal.pone.0006535.g002
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pro-apoptotic protein Bax while the expression of anti-apoptotic
protein Bcl-XL decreased by 50%. The over-all ratio of pro- and
anti-apoptotic proteins in control cells was 1 which increased
significantly (to approximately 4) in RWE-treated cells. Inhibitionof
AR not only controlled the expression of these proteins but it also
maintained the ratio to approximately one. These results suggest
that AR inhibition prevented the RWE-induced alteration in the
ratio of pro-and anti-apoptotic proteins and thereby promoted cell
survival and inhibited apoptosis in these cells.
AR inhibition prevents RW-induced over-expression of
cell cycle proteins in SAEC
As we showed above RWE induces epithelial cell injury and
apoptosis that affects the cell cycle progression. The number of
cells entering the cell division cycle is regulated by a fine balance of
cell cycle proteins. We therefore examined whether AR inhibition
will affect the level of cell cycle proteins in RWE-treated SAEC. As
shown in Fig. 4(I) C, RWE caused .3.5 fold increased expression
of cyclin D1 and .2.5 fold increased expression in E2F2 proteins.
Inhibition of AR by zopolrestat significantly (.90%) prevented the
increase in the expression of cell cycle proteins. These results
suggest that inhibition of AR is critical to maintaining the cell cycle
under oxidative stress and prevents cells from undergoing
apoptosis.
AR inhibition prevents RWE-induced activation of NF-kB
and AP1
We next examined the effect of AR inhibition on RWE-induced
activation of NF-kB and AP1 because these transcription factors are
Figure 3. Pharmacological inhibition or genetic ablation of AR prevents RWE-induced secretion and expression of inflammatory markers
in SAEC. Approximately 2610
5 SAEC were seeded in 6-well plates and incubated until 80% confluency. (I). The cells then starved in serum-free basal medium
with or without AR inhibitor, zopolrestat, at 37uC for 24 h. The cells were incubated with RWE (150 mg/ml) for an additional 24 h. The medium was harvested,
centrifuged and supernatant was used for the determination of IL-6 (A), IL-8 (B) and PGE2 (C) with respective ELISA kits following supplier’s manuals. Bars
represent Mean6SD (n=4);
*p,0.05 Vs Control;
##p,0.001 Vs Control;
###p,0.01 Vs RWE alone
**p,0.05 Vs RWE alone. zop, zopolrestat; RWE, ragweed
pollen extract. (II). SAEC were transfected with AR-SiRNA or scrambled-SiRNA in basal medium. After 48 h, medium was replaced with fresh basal medium and
the cells were treated with RWE (150 mg/ml) and incubated for an additional 24 h. The medium was harvested, centrifuged and supernatant was used for the
determination of IL-6 (A), IL-8 (B) and PGE2 (C) with respective ELISA kits following supplier’s manuals. Bars represent Mean6SD (n=4);
#p,0.01 Vs Control;
##p,0.001 Vs Control;
###p,0 . 0 1V sR W Ea l o n e .C ,c o n t r o l ;C S i ,s c r a m b l e ds i R N A ;A R S i ,a l d o s er e d u c t a s es i R N A ;z o p ,z o p o l r e s t a t ;R W E ,r a g w e e dp o l l e n
extract. (III). SAEC were starved in serum-free basal medium with or without zopolrestat for 24 h. The cells were treated with RWE (150 mg/ml) for 6 h. Total
RNA was extracted as described in the methods and IL-6 (A), IL-8 (B) and COX-2 (C) mRNA expression was determined using Qiagen RT-PCR kit and b-Actin was
used as loading control. A representative gel showing amplified PCR products is shown (n=3). zop,z o p o l r e s t a t ;R W E ,r a g w e e dp o l l e ne x t r a c t .
doi:10.1371/journal.pone.0006535.g003
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markers. As shown in Fig. 4(II) A, RWE caused approximately 4-fold
activation of NF-kB and AP-1 and zopolrestat significantly (.80%)
prevented RWE-induced NF-kB activation and nuclear transloca-
tion. Zopolrestat alone did not affect the basal NF-kBa c t i v i t yi nt h e
SAEC. To further confirm NF-kB activation by RWE, we used NF-
kB-dependent secretory alkaline phosphatase (SEAP) reporter assay
and found that RWE significantly (.3-fold) induced NF-kB-
dependent SEAP activation in SAEC and AR inhibitor, zopolrestat,
caused .60% inhibition (Fig. 4(II) B). However, zopolrestat alone did
n o ta f f e c tt h eN F - kB-SEAP activity. These results validated our
measurement of DNA binding activity of NF-kB by gel-shift assay.
Based on these observations, we conclude that inhibition of AR
prevented RWE-induced activation of NF-kB, which could activate
the expression and synthesis of inflammatory markers in SAEC.
AR inhibition prevents RWE-induced accumulation of
eosinophils in mice airway
Since inflammatory response of RWE challenge to SAEC was
blocked significantly by AR inhibition, we tested whether this
approach would work in the animal model as well. We therefore
sensitized and challenged the BALB/c mice with RWE- or carrier-
treated without or with AR inhibitor. As shown in Fig. 5(I) there
was a robust airway inflammation as measured by accumulation of
inflammatory cells in bronchoalveolar lavage (BAL) fluid and sub-
epithelium in RWE-sensitized and - challenged animals. In the
mice treated with AR inhibitor there was significantly (p,0.002)
less inflammation as determined by the number of eosinophils in
BAL fluid. Similarly, perivascular and peribronchial inflammation
and cell composition in the BAL fluid induced by RWE challenge
was significantly prevented by AR inhibitor treatment (Fig. 5(II)).
Figure 4. Inhibition of AR prevents RWE-induced expression and activation of inflammatory, apoptotic and cell cycle proteins and
redox-sensitive transcription factors NF-kB and AP-1 in SAEC. (I) Approximately 2610
5 SAEC were seeded in 6-well plates and incubated
until 80% confluency. The cells were starved in serum-free basal medium with or without zopolrestat for 24 h. The cells were treated with RWE
(150 mg/ml) for 24 h and cell lysate was prepared. Immunoblotting was performed using antibodies against (A) COX-2, iNOS, (B) Bcl-XL, Bax, and (C)
Cyclin D1, E2F2 to determine the expression of various proteins. GAPDH was used as loading control. Representative blots are shown (n=3), numbers
below the blots represent fold changes. Lanes: 1, control; 2, RWE; 3, control+zop; 4, RWE+zop. zop, zopolrestat; RWE, ragweed pollen extract. (II) (A)
For EMSA, approximately 2610
6 SAEC were seeded in T-150 cm
2 flasks and incubated until 80% confluency. The cells were starved in serum-free
basal medium with or without zopolrestat for 24 h. The cells were treated with RWE (50 mg/ml) for 3 h. Nuclear extract was prepared and EMSA was
performed to assess the DNA binding activity of NF-kB and AP-1. Lanes: 1, control; 2, RWE; 3, control+zop; 4, RWE+zop. zop, zopolrestat; RWE,
ragweed pollen extract. (B) Approximately, 1610
5 SAEC were plated in 24-well plate and growth-arrested by preincubatin in serum-free basal
medium with AR inhibitor or carrier for 24 h followed by transfection with NF-kB-pSEAP vector or control (pTAL) vector. After 6 h, transfected cells
were incubated with RWE (50 mg/ml) for 48 h. Medium was collected, cleared by centrifugation and NF-kB-dependent reporter SEAP activity was
measured by chemiluminescence’s method essentially as described by the manufacturer. Bars represent Mean6SD (n=4).
#p,0.001 Vs. Control;
*p,0.01 Vs RWE. zop, zopolrestat; RWE, ragweed pollen extract.
doi:10.1371/journal.pone.0006535.g004
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hyperreactivity in mice airway
Excessive mucin production by airway epithelium is character-
istic of allergic asthma and its prevention is the main goal to treat
allergic episodes in susceptible individuals [26]. Therefore, we next
examined the mucin levels in the BAL fluid by ELISA using anti-
MUC5ac monoclonal antibodies and found that mucin levels
increased ,25-folds in RWE-challenged mice as compared to
control and AR inhibition prevented it significantly (p,0.003).
Similarly, mucin production in the epithelial cells as assessed by
periodic acid Schiff (PAS)-staining of lung sections (Fig. 6(I), inset)
was also prevented by AR inhibition. In addition, whole body
unrestrained plethysmography was used to quantitatively measure
airway responsiveness in mice after methacholine challenge. As
shown in Fig. 6(II), enhanced pause (Penh) elevated dose-
dependently in response to methacholine challenge as compared
to control mice treated with PBS alone. Treatment of mice with
AR inhibitor decreased the Penh values significantly (p,0.01)
from methacholine (80 mg/ml) alone-challenged mice. These
results indicate that AR inhibition significantly prevented the
patho-physiological effects of allergic asthma in murine model.
AR inhibition prevents RWE-induced cytokines and
chemokines secretion in mice airway
Th2 type cytokines such as IL-4, IL-5 and chemokines have
been implicated in the pathology of allergic asthma [27]. Also, the
Figure 5. AR inhibition prevents RWE-induced accumulation of eosinophils in mice. (I) Determination of eosinophils in BAL. The Balb/c
mice were sensitized and challenged with PBS, RWE, ARI alone, or ARI+RWE and 72 h later lungs were lavaged with ice-cold PBS and differential cell
counts were performed on cytocentrifuge preparations stained with hematoxylin and eosin. Bars represent Mean6SD (n=6–8),
#p,0.002 Vs RWE.
Inset: representative fields of hematoxylin and eosin preparations were photographed (magnification 690). (II) Determination of eosinophils in
peribronchial and subepithelial regions of lung. Sensitized BALB/c mice were challenged as in (I), 72 h later lungs were excised, fixed with 4%
paraformaldehyde, embedded in paraffin, and sectioned to 5 mm. Sections were stained with hematoxylin and eosin. Photomicrographs were
acquired by photometrix CoolSNAP Fx camera mounted on a NIKON Eclipse TE 200 UV microscope. A representative field for each group is shown
(magnification: 630). PBS, phosphate buffer saline; RWE, ragweed pollen extract; ARI, aldose reductase inhibitor
doi:10.1371/journal.pone.0006535.g005
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during allergic inflammation [28]. Therefore, we determined the
effect of AR inhibition on the RWE-induced expression of Th2
type cytokines and chemokines in lung by quantitative RT-PCR.
As shown in Table 1, RWE challenge caused increased expression
of interleukin (IL)-4, IL-5, IL-6, IL-10 and IL-13, and chemokines
such as Chemokine (C-C motif) ligand (CCL)-4 and CCL-5 which
was significantly prevented by AR inhibition. There was no
change in the level of expression of these cytokines and
chemokines in AR inhibitor alone treated mice lungs.
Discussion
Among many factors, weed pollens are associated with the
allergic asthma causing loss of human work hours and severe
health problems, sometimes leading to life threatening conditions.
Ragweed pollens are among many seasonal weed pollens that have
been shown to induce severe allergic response in susceptible
individuals. Ragweed pollens or their extract have been shown to
possess intrinsic ROS producing machinery due to their intrinsic
NAD(P)H oxidase [25,29]. We have shown that RWE adminis-
Figure 6. AR inhibition prevents RWE-induced mucin production and methacholine –induced airway hyper-responsiveness in mice.
(I) The lungs were lavaged with ice-cold PBS 72 h after RWE challenge. Mucin levels in the BAL were determined by ELISA using anti-MUC5ac
monoclonal antibody. Bars represent Mean6SD (n=6),
#p,0.003 Vs RWE. Inset: sections were stained with periodic acid Schiff (PAS)-stain to
visualize mucin producing cells. A representative field is shown (magnification:630). (II) The changes in pause of breathing ‘enhanced pause’ (PENH)
as an index of airway obstruction were measured by whole-body plethysmography. Mice were placed in a barometric plethysmographic chamber
and Penh was determined and plotted against the increasing concentration of methacholine. Bronchopulmonary resistance was expressed as
enhanced pause=(expiratory time/relaxation time)-1)6(peak expiratory flow/peak inspiratory flow). Each data point represents mean6SD of 6 to 8
mice for each group.
*p,0.05,
**p,0.01 Vs RWE. ARI, aldose reductase inhibitor; RWE, ragweed pollen extract; PBS, phosphate buffer saline; PENH,
enhanced pause.
doi:10.1371/journal.pone.0006535.g006
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lungs and also increases the levels of oxidized glutathione (GSSG),
4-HNE, and malondialdehyde in the lung tissue [25]. Also, ROS
induced by environmental pollutants including diesel exhaust and
ozone have been recognized as the mediator of inflammation in
the airways causing and exacerbating allergic asthma [30–33].
Thus, it is well recognized that oxidative stress-induced changes in
airway epithelial cells physiology plays a central role in innate and
adaptive immune responses as well as mucosal inflammation [34].
Epithelial cells produce a large number of proinflammatory
cytokines and chemokines in response to allergens [27,34] which
further induce ROS - formation resulting in profound oxidative
stress.
It is well established that oxidative stress in airway epithelium
stimulates and initiates a molecular signal cascade leading to the
activation of NF-kB [35,36] which translocates to the nucleus. In
the nucleus NF-kB binds to DNA and transcribes inflammatory
markers such as interleukin (IL)-6, IL-8, macrophage inflamma-
tory protein 2 (MIP-2), granulocyte macrophage colony-stimulat-
ing factor (GM-CSF), intercellular adhesion molecule-1 (ICAM-1),
COX-2 and iNOS, which besides directly causing inflammation
also promote inflammatory cells infiltration [37–42]. The
infiltrated eosinophils, macrophages and T lymphocytes further
secrete various cytokines, chemokines and other inflammatory
markers that cause airway narrowing, hyperresponsiveness and
remodeling [41–43]. Thus, although the molecular events
associated with respiratory allergy and asthma are well under-
stood, the cure for this respiratory disorder which affects
approximately 20% of the US population is still elusive, especially
because of the lack of understanding how ROS mediates allergic
stimulant-induced activation of NF-kB. Here, we show for the first
time that inhibition of a polyol pathway enzyme, AR, could
attenuate RWE-induced airway inflammation and block the
inflammatory cells infiltration and expression of inflammatory
markers in the airway epithelial cells.
We have shown earlier that AR inhibition prevents oxidative
stress-induced signaling cascade that activates transcription
f a c t o r ss u c ha sN F - kB and AP-1 [9–14] which could prevent
the ROS-mediated airway inflammation. The airway epithelial
cells are known to produce ROS in response to many stimuli
including weed pollens and virus [25,44]. The locally produced
ROS oxidize the cell membrane phospholipids and generate lipid
hydroperoxides which impair membrane function such as
membrane transport, dysfunction of channel proteins, and loss
of fluidity leading to tissue injury [3]. The lipid peroxidation
products, including the most abundant and reactive lipid
aldehydes such as 4-HNE, have been shown in the airways of
experimental animals [3,25]. 4-HNE is known to induce various
cellular events including activation of signaling cascade leading
to cytotoxicity [45,46]. Also, 4-HNE readily forms conjugates
with glutathione (GS), GS-HNE. In vascular smooth muscle cells
and murine macrophages we have recently shown that AR-
catalyzed reduced product of GS-HNE conjugates, glutathionyl-
1,4-dihydroxynonane (GS-DHN), caused activation of NF-kB-
dependent signaling, leading to cytotoxicity [10,47]. These data
designated a novel role for AR-catalyzed reduced product, GS-
DHN, which could be responsible for activation of inflammatory
signaling during oxidative stress induced by various stimuli
including pathogens, allergens and environmental pollutants.
These results indicate that inhibition of AR that blocks the
reduction of glutathione-lipid aldehyde conjugate could be a
novel approach to prevent inflammation.
Antioxidants and ROS scavengers such as ascorbic acid, N-
acetyl-L-cysteine (NAC), and superoxide dismutase (SOD) have
been shown to be effective in controlling ROS-mediated airway
inflammation [48,49]. Increased dietary intake of ascorbic acid has
been shown to improve lung functions in asthma patients [50].
Similarly, NAC has been shown to have protective effects both in
vitro and in vivo against oxidative stress in airway inflammation [51–
53]. These evidences suggest that quenching ROS or blocking its
effect on airway epithelial cells could be a potential strategy to
prevent inflammation and tissue injury during allergic asthma. We
observed that in SAEC, AR inhibition significantly prevents ROS
formation by RWE challenge and thereby prevents ROS-induced
cytotoxicity, including cellular apoptosis. These results suggest that
AR inhibition could successfully attenuate the effect of ROS as
well as ROS formation in SAEC.
Increased levels of inflammatory markers including cytokines
such as interleukins (IL-6), chemokines such as IL-8 and other
inflammatory mediators such as PGE2 by airway epithelial cells
are the hallmarks of inflammatory response in allergic asthma
[54]. Primarily, these inflammatory markers are released by
Table 1. AR inhibition prevents RWE-induced expression of cytokine and chemokines in mice lungs.
Cytokine and chemokines Abbrev. ARI alone (n=5) RWE alone (n=5–6) RWE+ARI (n=7) P value
Interleukin 4 IL-4 1.0760.13 15.3760.71 3.8460.44 P=0.0012
Interleukin 5 IL-5 1.0960.09 6.8460.63 2.8460.14 P=0.0023
Interleukin 6 IL-6 0.8760.16 3.1160.21 1.9460.53 P=0.017
Interleukin 8 IL-8 0.9760.03 4.5860.77 2.1860.31 P=0.0019
Interleukin 10 IL-10 0.9360.011 6.6460.21 3.1860.21 P=0.022
Interleukin 13 IL-13 1.1760.23 9.1460.29 3.1860.66 P=0.017
Interleukin 17 IL-17 1.0960.019 6.2460.27 2.5060.10 P=0.031
Interleukin 18 IL-18 1.1760.011 2.6460.47 1.6460.47 P=0.027
Chemokine (C-C motif) ligand 4 CCL4 1.0160.09 5.1860.19 1.1860.59 P=0.019
Chemokine (C-C motif) ligand 5 CCL5 1.1260.22 7.3860.29 4.1860.79 P=0.033
Tumor necrosis factor alpha TNF-a 0.9660.14 4.8360.53 2.3360.41 P=0.029
Total RNA was isolated from homogenized lungs (n=5–7), one microgram of total RNA from each sample was transcribed into first-strand cDNA and quantitative RT-
PCR was conducted for selected genes using specific forward and reverse primers. The levels of RNA for the target sequences were determined by melting curve
analysis. The values presented here are fold-change over the control. RWE, ragweed pollen extract; ARI, aldose reductase inhibitor.
doi:10.1371/journal.pone.0006535.t001
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and dispose off the allergens by recruiting immune cells. However,
excessive allergen exposure causes an overwhelming response by
epithelial cells resulting in increased ROS formation leading to
activation of redox-sensitive transcription factors such as NF-kB
and AP-1 [36,42] which transcribe various inflammatory markers
that cause cytotoxicity and damage to airway resulting in the
pathogenesis of allergic asthma. Therefore, blocking the synthesis
and release of the inflammatory markers could potentially prevent
asthma pathogenesis. Anti-interleukin antibody treatment has
been suggested to have considerable therapeutic potential for
asthma and allergy [55–58]. Similarly, various studies have shown
increased iNOS expression in airway epithelium of asthma
patients [59,60]. COX-2 has also been found to be elevated
during asthma [60]. COX-2 and iNOS catalyze oxidative stress-
inducible production of PGE2 and NO, respectively which play
important role in the pathogenesis of asthma and have been
suggest as possible therapeutic targets [60]. In the present study we
have shown that pharmacological inhibition as well as genetic
ablation of AR message significantly (70–90%) inhibited RWE-
induced expression of these inflammatory markers in SAEC which
suggests that AR is a key mediator in RWE-induced inflammation
and inhibition of AR, that we have shown earlier prevents the
oxidative stress-induced generation of COX-2 and iNOS, would
prevent allergen-induced airway inflammation.
Since our ultimate goal is to develop an effective therapeutic
intervention to allergic respiratory disorders, we tested whether
significant prevention of inflammatory response of RWE challenge
in in-vitro cellular model would work in the animal model of
allergic asthma as well. The recruitment of eosinophils in the
airway plays an important role in the pathogenesis of allergic
asthma [41,43]. Studies with RWE–challenged mice have shown
that inflammatory cells including eosinophils infiltrate the airway
[25,49]. A study using suicidal signals specific to eosinophils in
mice showed that eosinophils infiltration is mandatory for the
pathology of asthma [61]. We, using murine model of RWE-
induced airway inflammation, observed that treatment with AR
inhibitor significantly prevented the airway inflammation and
recruitment of eosinophils in BAL fluid and subepithelial spaces.
In addition, RWE-induced hyperresponsiveness and excessive
mucin production by airway epithelium and Th2 type cytokines
and chemokines gene expression in sensitized mice were also
significantly prevented by AR inhibition. These data with animal
model of RWE-induced airway inflammation confirm our in-vitro
finding with human primary airway epithelial cells and suggest
that AR inhibitors could be initiated for controlled clinical trial in
allergic asthma patients. A recent report suggests that AR
inhibitors such as zopolrestat and fidarestat have been found to
be safe in clinical trials and did not show any major side effects
[18].
Thus, with predicted increase in the ragweed pollen production
under increased environmental CO2 condition in future climate
there is strong likelihood of prevalence of allergic disorders [62]. In
view of limitations and side effects of present day anti-
inflammatory medication to treat allergic disorders, it is imperative
to search for a pharmacological agent with minimal side effects.
The evidences presented in this report indicate that AR inhibitors
could be a novel approach to control the allergen-induced
inflammation in the airway epithelial cells. In summary, we have
presented the evidence that AR mediates the respiratory
inflammatory response during ragweed pollen-induced allergic
asthma and have provided a novel concept that inhibition of AR
could be a therapeutic approach in the treatment of allergic airway
inflammation.
Materials and Methods
Reagents
Small airway epithelial basal medium (SABM), and small airway
epithelial growth media (SAGM
TM) bulletkit; and one Reagent-
pack
TM containing Trypsin 0.025%/EDTA 0.01%, Trypsin
neutralizing solution and HEPES buffered saline solution were
purchaged from Cambrex Bio Sciences Walkersvillle, Inc.
(Walkersville, MD). Sorbinil and Zopolrestat were obtained as
gift from Pfizer (New York, NY). Dimethyl sulfoxide (DMSO) was
obtained from Fischer scientific (Pittsburg, PA). Ragweed pollen
extract (RWE) was purchased from Greer’s laboratory (Lenoir,
NC). Nitrite/Nitrate and PGE2 assay kits were obtained from
Cayman Chemical Inc (Ann Arbor, MI). Human IL-6 and IL-8
ELISA kits were from Diaclone (Stamford, CT) and R&D systems,
respectively. Antibodies against COX-2, iNOS, Bcl-XL, Bax,
GAPDH, cyclin-D1 and E2F2 were from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA); and antibodies against phospho-IkB
were from Cell signaling (Danvers, MA). Dihydroethidium (DHE)
fluorescent dye was purchased from Molecular Probes, Invitrogen
(Carlsbad, CA) and polyclonal antibodies against human recom-
binant AR were made for us by Alpha diagnostic intl. (San
Antonio, TX). The reagents used in the electrophoretic mobility
shift assay (EMSA) and Western blot analysis were obtained from
Sigma. All other reagents used were of analytical grade.
Cell Culture
Primary human Small Airway Epithelial Cells (SAEC) obtained
from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD)
were normal human SAEC harvested from distal airspace of
18 yrs old male donor. The cells were cultured according to the
supplier’s instructions at 37uC in humidified atmosphere contain-
ing 95% air and 5% CO2 in small airway epithelial basal medium
(SABM) with supplements containing 52 mg/ml bovine pituitary
extract, 0.5 ng/ml human recombinant epidermal growth factor
(EGF), 0.5 mg/ml epinephrine, 1 mg/ml hydrocortisone, 10 mg/
ml transferrin, 5 mg/ml insulin, 0.1 ng/ml retinoic acid (RA),
6.5 ng/ml triiodothyronine, 50 mg/ml Gentamicin/Amphoteri-
cin-B (GA-1000), and 50 mg/ml fatty acid-free bovine serum
albumin (BSA).
Annexin-V Staining and Flow Cytometry
Approximately 2610
5 SAEC per well were plated in 6-well
plates in triplicate for each group. The medium was replaced with
serum-free SABM with or without zopolrestat (20 mM) and
incubated for 24 h. The cells were treated by RWE (150 mg/
mL) and incubated for 18 h. Apoptotic cell death was examined
using the annexin-V-FITC/propidium iodide (PI) (molecular
probes, Invitrogen) according to the manufacturer’s instructions.
Twenty thousand events were acquired for each sample and
analyzed by flow cytometry using the LYSIS II software
(FACScan, BD Pharmingen).
In situ detection of superoxide
Dihydroethidium (DHE, Molecular Probes) staining was carried
out to assess the ROS production. Briefly, Approximately 1610
5
SAEC were seeded on chambered slides and starved in serum-free
SABMwithorwithout AR inhibitor for24 h.Thecellsweretreated
with RWE (150 mg/mL) for 16 h. SAEC were rinsed with cold PBS
and incubated in PBS containing DHE (2.5 mmol/L) at 37uC for 15
minutes. Cells were rinsed in PBS and mounted with mounting
medium with DAPI (Vector Laboratories Inc., Burlingame, CA).
The image of ethidium staining was observed and photomicro-
graphs were acquired with a Nikon epifluorescence microscope with
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demonstrated by strong red fluorescent labeling.
Electrophoretic Mobility Shift Assay (EMSA)
Approximately 90% confluent SAEC in T-150 cm
2 culture
flasks were incubated with AR inhibitor or carrier for 24 h in
starving medium, followed by treatment with RWE (50 mg/ml) for
2 h at 37uC. The nuclear extracts were prepared as described [63].
The Consensus oligonucleotides for NF-kB and AP-1 transcription
factors were 59-end labeled using T4 polynucleotide kinase. EMSA
was performed as described earlier [64].
NF-kB-dependent secretary alkaline phosphatase
expression (SEAP) reporter Assay
Approximately 1610
5 SAEC per well were plated in 24-well
plates, serum-starved in SABM for 24 h with or without AR
inhibitor, zopolrestat (20 mM), and transiently transfected with
pNF-kB-secretory alkaline phosphatase (SEAP) construct or
control plasmid pTAL-SEAP DNA (Clontech, Palo Alto, CA)
using the LipofectAMINE Plus reagent. After 6 h of transfection,
medium was replaced with fresh medium and cells were treated
with RWE (50 mg/mL) for 48 h. The cell culture medium was
harvested, centrifuged and supernatant was analyzed for SEAP
activity, essentially as described by the manufacturer (Clontech,
Palo Alto, CA), using a 96-well chemiluminescence plate reader.
RNA Interference Ablation of AR in SAEC
Approximately 2610
5 SAEC were plated in 6-well plates and
grown until ,80% confluency. The cells were transfected with
AR-siRNA (AAC GCA TTG CTG AGA ACT TTA) or
scrambled siRNA (AAC ACG GCT TGA ATG ACT ATA;
control) to a final concentration of 100 nM using RNAiFect
TM
transfection reagent (Qiagen). The cells were further incubated for
48 h at 37uC, and AR expression was determined by measuring
AR protein by Western blot analysis using rabbit anti-AR
polyclonal antibodies.
Determination of inflammatory markers IL-6, IL-8 and
PGE2
The SAEC were plated in 6-well plates at a density of 2610
5
cells per well in triplicate for each group. After 24 h, the cells were
pretreated in serum-free SABM with or without zopolrestat
(20 mM) or transfected with AR siRNA as described above. The
growth-arrested and AR ablated cells were stimulated with RWE
(150 mg/mL) for another 24 h in serum-free medium. The
medium was collected from each well, centrifuged and supernatant
was analyzed by using specific ELISA kits for IL-6 (Diaclone,
Stamford, CT), IL-8 (R&D systems Inc, Minneapolis, MN) and
PGE2 (Cayman Chemical Co., Ann Arbor, Michigan) according
to the manufacturer’s instructions.
Determination of gene expression of IL-6, IL-8 and COX-2
by RT-PCR
The SAEC were grown in 6-well plates at a density of
approximately 2610
5 cells per well. After approximately 80%
confluence, cells were serum-starved in the presence or absence of
zopolrestat (20 mM) for 24 h and then stimulated with 150 mg/ml
RWE for 6 h. Total RNA from SAEC was isolated by using
RNeasy kit (Qiagen) as per supplier’s instructions. Aliquots of
RNA (0.5–1.0 mg) isolated from each sample were reverse
transcribed with Omniscript and Sensiscript reverse transcriptase
one-step RT-PCR system with HotStar Taq DNApolymerase
(Qiagen) at 55uC for 30 min followed by PCR amplification. The
oligonucleotide primer sequences were as follows: 59-AT-
GAACTCCTTCTCCACAAGCGC-39 (sense) and 59-GAA-
GAGCCCTCAGGCTGGACTG-39 (antisense) for IL-6; 59-
ATGACTTCCAAGCTGGCCGTGGCT-39 (sense) and 59-
TCT CAGCCCTCTTCAAAAACTTCTC-39 (antisense) for IL-
8; 59-TGAAACCCACTCCA AACACAG-39 (sense) and 59-
TCATCAGGCACAGGAGGAAG-39 (antisense) for COX-2;
and 59-ATCTGGCACCACACCTTCTACAATGAGCTGCG-
39 (sense) and 59-CGTC ATACTCCTGCTTGCTGATCCA-
CATCTGC- 39 (antisense) for b-actin. PCR was carried out in a
PCR Sprint thermal cycler (Thermo electron corporation,
Milford, MA) under the following conditions: initial denaturation
at 95uC for 15 min followed by 35 cycles of 94uC for 1 min, 62uC
for 1 min, 72uC for 1 min, followed by 72uC for 10 min for final
extension. PCR products were electrophoresed with 1.5% agarose-
1X TAE gels containing 0.5 mg/ml ethidium bromide. The
densitometric analyses of the blots were performed by using
Kodak 1D image analysis software.
Western blot analysis
Forty micrograms of cytoplasmic protein extracts, prepared as
described earlier were resolved on 10% SDS-PAGE. After
electrophoresis, the proteins were electro transferred to a
nitrocellulose membrane, blocked with 5% nonfat milk in TBST,
and probed with antibodies against COX-2, iNOS, Bcl-XL, Bax,
cyclin D1, E2F2 (1:1,000 dilution) and GAPDH (1:10,000 dilution)
for 2 h. The blots were then washed, exposed to HRP-conjugated
secondary antibodies (1:5,000 dilution) for 1 h, and the antigen-
antibody complex was detected by enhanced chemiluminescence
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Animals
BALB/c mice were purchased from Harlan Sprague-Dawley
(San Diego, CA, USA). All animal experiments were performed
according to the National Institutes of Health Guide for Care and
Use of Experimental Animals and approved by University of
Texas Medical Branch Animal Care and Use Committee.
Sensitization and challenge of animals
Eight-weeks-old female animals were sensitized with RWE as
we have previously described [21,25,28]. Briefly, mice were
sensitized with two intraperitoneal administrations of endotoxin-
free RWE 150 mg/100 ml, combined with Alum adjuvant in a 3:1
ratio, on days 0 and 4. On days 9 and 10, animals were treated
with AR inhibitor (i.p. 25 mg/kg body weight) every 12 h for total
duration of 48 h. On day 11, parallel groups of mice (n=6–8) were
challenged intranasally with RWE (100 mg), along with AR
inhibitor. Control groups of mice were challenged with equivalent
volumes of PBS.
Evaluation of allergic inflammation
To evaluate inflammation, animals from all experimental
groups were euthanized on day 14 with ketamine (135 mg/kg
body wt) and xylazine (15 mg/kg body wt), and the lungs were
lavaged with two 0.8 ml aliquots of ice-cold PBS. The cells were
collected by centrifugation (1000 g, for 10 min at 4uC), re-
suspended in one ml PBS and total cell counts were determined.
Differential cell counts were performed on cytocentrifuge
preparations stained with hematoxylin and eosin. After broncho-
alveolar lavage (BAL), the lungs were fixed with 4% paraformal-
dehyde, embedded in paraffin, and sectioned to 5 mm. Lung
sections were stained with hematoxylin and eosin [25]. Perivas-
cular and peribronchial inflammation and cell composition in the
Aldose Reductase in Asthma
PLoS ONE | www.plosone.org 11 August 2009 | Volume 4 | Issue 8 | e6535BAL were evaluated by a pathologist, blinded to treatment groups,
to obtain data for each lung. The representative fields were
photographed with a Photometrix CoolSNAP Fx camera mounted
on a NIKON Eclipse TE 200 UV microscope.
Mucin production by the epithelial cells was assessed by
periodic acid Schiff (PAS)-staining of formalin-fixed, paraffin-
embedded lung sections. The stained sections were analyzed as
above and representative fields were photographed with a
Photometrix CoolSNAP Fx camera mounted on a NIKON
Eclipse TE 200 UV microscope [25,28].
To determine mucin levels, BAL was centrifuged at 12,000 rpm
for 10 min at 4uC, and the supernatants were kept at 280uC until
assayed. MUC5ac levels in the BAL were assessed by ELISA using
commercially available anti-MUC5ac monoclonal antibody (I-
13M1) (Lab Vision, Fremont, CA, USA). Briefly, MUC5ac
present in the BAL was captured to a microtiter plate and a
second antibody conjugated to biotin was added. After 30 min
incubation with streptavidin-horseradish peroxidase (HRP) plates
were washed and peroxidase substrate was added to obtain
colorimetric product, which was quantified by spectrometry. Data
are expressed as arbitrary units relative to a MUC5ac standard
curve that was included on each plate [25].
Airway responsiveness was measured in unrestrained, conscious
mice 3 days after the last challenge. Mice were placed in a
barometric plethysmographic chamber, and baseline readings
were taken and averaged for 3 min. Aerosolized methacholine in
increasing concentrations (from 10 to 80 mg/ml) were nebulized
through an inlet of the main chamber for 3 min. Readings were
taken and averaged for 3 min after each nebulization and
‘enhanced pause’ (PENH) was determined. PENH, a dimension-
less value, represents a function of the ratio of peak expiratory flow
to peak inspiratory flow and a function of the timing of expiration,
was calculated as (expiratory time/relaxation time
21)6(peak
expiratory flow/peak inspiratory flow) according to the manufac-
turers’ protocol. PENH correlates with pulmonary airflow
resistance or obstruction and was used as a measure of airway
responsiveness to methacholine.
RNA isolation
Total RNA was isolated from homogenized lungs of sensitized,
RWE-challenged mice (with and without ARI) using Ambion’s
RNAqueous Kit (Ambion, Austin, TX) according to manufactur-
er’ commendations. RNA concentration was quantified using a
DU530 Beckman spectrophotometer (Beckman Coulter, Full-
erton,CA) at 260 nm. The 260/280 nm absorbance ratio was used
to assess the purity of isolated RNA.
Quantitative RT-PCR
One microgram of total RNA from each sample was transcribed
into first-strand cDNA using SYBR GreenER two step qRT-PCR
kit from ABI Prism (Invitrogen, Carsbad, CA). For selected genes
forward and reverse primers were purchased from SABiosciences
Corporation (Frederick, MD). Interleukin 3 (Cat # PPM03012E);
Interleukin 4 (Cat # PPM03013E); Interleukin 5 (Cat #
PPM03014E); Interleukin 8 receptor (Cat # PPM05308E0),
Interleukin 10 (Cat # PPM03017B); Interleukin 13 (Cat #
PPM03021A); Interleukin 17B (Cat # PPM03540A); Interleukin
18 (Cat # PPM03112B ); Chemokine (C-C motif) ligand 4 (Cat #
PPM02948F); Chemokine (C-C motif) ligand 5 (Cat #
PPM02960E ); tumor necrosis factor alpha (Cat # PPM03113F);
Interferon gamma (Cat# PPM03113F). Internal controls were
hypoxanthine guanine phosphoribosyl transferase 1 (Cat #
PPM03559E) and glyceraldehyde-3-phosphate dehydrogenase
(Cat # PPM02946E). PCR was conducted under the following
conditions: denaturation at 95uC for 10 min, 1 cycle, followed by
40 cycles of denaturation at 95uC for 15 s, annealing and
elongation at 60uC for 60 s. The levels of RNA for the target
sequences were determined by melting curve analysis using the
ABI PRISM 7000 sequence Detector software (Applied Biosys-
tems, Foster City, CA).
Statistical analysis
For the cell culture experiments data presented are mean6SD
and P values were determined by unpaired, two-tailed Student’s t
test. For animal studies, data collected from in vitro and in vivo
experiments were analyzed by ANOVA, followed by Bonferroni
post-hoc analyses for least significant difference. For quantitative
RT-PCR data statistical analysis was done by unpaired, two-tailed
t-test using Graph-pad prism software. p,0.05 was considered as
statistically significant.
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